Dr Deepa Pakianathan has been in biotech VC for more than twenty years, having seen multiple cycles of biotech boom-and-bust. She gives us her assessment of the IO landscape, her best advice for capital raising and her insight based on how her past experiences with CEOs have informed her approach as a new CEO.
Lead Editorial
The Current State of the IO Fundraising Landscape from a Long-Time Biotech Investor
Featured Editorial
Editorial by Category
Clinical Trial Operations
View All
DPHARM® Announces First Slate of Keynotes for 15th Annual Event
Leveraging AI to Streamline Clinical Development, with Formation Bio’s CDO
How Memorial Sloan Kettering Cancer Center Scaled EHR-to-EDC Technology
Conference Forum Announces the Partnerships with Sites Summit to Improve Patient Enrollment
Immuno-Oncology and Cell Therapy
View All
Drug Delivery
View All
Patients as Partners in Clinical Research and Patient Access
View All
CRO Perspective on Connecting Advocacy and Industry to Advance Patient-Centric Medicine
How Patient Involvement Gets Done to Better Support Access, Decision-making and Medicine Development: Patients as Partners 2025 Recap
What Clinical Research Means to Patients in Ukraine, and How Industry Sponsors Can Help
Biogen on Digital Innovations to Increase Trial Access and Enhance Patient Experiences
Biotech CMO/R&D Leadership
View All
CRAACO: Clinical Research as a Care Option
View All
Conference Forum Announces the Partnerships with Sites Summit to Improve Patient Enrollment
How CMOs can Champion Patient-Centric Drug Development
What Clinical Research Means to Patients in Ukraine, and How Industry Sponsors Can Help
Biogen on Digital Innovations to Increase Trial Access and Enhance Patient Experiences
Women Leadership in Biotech
View All
The Conference Forum Sees Record Growth in Attendees Across 2024 Events, Bringing Together Leaders in Medicine Development
Women Leadership in Immuno-Oncology: 2022 Celebration Series
Women Leadership in Immuno-Oncology: 2021 Celebration Series
